ERR2208940
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- DNA_REPAIR+0.400
- MTORC1_SIGNALING+0.300
- GLYCOLYSIS+0.200
- SPERMATOGENESIS+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- APICAL_SURFACE+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- ANGIOGENESIS-0.300
- APOPTOSIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.924 |
| 2 | SRR10900551 | — | — | 0.914 |
| 3 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.906 |
| 4 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.904 |
| 5 | ERR2208894 | — | — | 0.897 |
| 6 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.892 |
| 7 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.886 |
| 8 | TCGA-94-8035-01A-11R-2247-07 | — | cohortSQ1 | 0.885 |
| 9 | MBCProject_4634_T1_RNA | — | E | 0.885 |
| 10 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |